Bluebird Bio Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE--bluebird bio, Inc. (Nasdaq: BLUE) today presented new results for betibeglogene autotemcel (beti-cel), a deeply studied investigational gene therapy, that demonstrate adult and pediatric patients living with -thalassemia (beta-thal) who require regular red blood cell (RBC) transfusions can produce normal or near-normal levels of total hemoglobin and continue to remain transfusion-free, and achieve stable iron markers, through up to seven years of follow-up (n

Zacks Investment Research upgraded shares of bluebird bio (NASDAQ:BLUE) from a hold rating to a buy rating in a report published on Monday, Zacks.com reports. The firm currently has $10.00 price target on the biotechnology companys stock. According to Zacks, bluebirds Q3 earnings and revenues missed estimates. In November 2021, the company successfully separated the [] The post Zacks Investment Research Upgrades bluebird bio (NASDAQ:BLUE) to Buy appeared first on ETF Daily News .

The global Cell And Gene Therapy market is expected to reach US$ 14.6 Billion by 2027, with a CAGR of 13.8% from 2021 to 2027. The high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments

Equities analysts expect bluebird bio, Inc. (NASDAQ:BLUE) to post ($1.68) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for bluebird bios earnings, with the lowest EPS estimate coming in at ($2.68) and the highest estimate coming in at ($0.95). bluebird bio posted earnings of ($3.01) per []

Wells Fargo & Company MN cut its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 23.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 196,313 shares of the biotechnology companys stock after selling 60,703 shares during the quarter. Wells Fargo & Company []

Parametric Portfolio Associates LLC raised its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 91.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 174,804 shares of the biotechnology companys stock after purchasing an additional 83,426 shares during the quarter. Parametric Portfolio Associates LLC owned approximately 0.26% []

There's an entire galaxy full of better places to invest your money.

There's an entire galaxy full of better places to invest your money.

bluebird bio Inc. (NASDAQ:BLUE) concluded the trading at $10.05 on Wednesday, December 01 with a fall of -0.59% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $10.11 and 5Y monthly beta was reading 1.57 with its price kept floating in the bluebird bio Inc. (BLUE) Is On The Launchpad, Waiting For Long-Term Buyers. Read More »

Bank of America Corp DE lowered its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 32.0% in the second quarter, Holdings Channel.com reports. The firm owned 183,087 shares of the biotechnology companys stock after selling 86,337 shares during the period. Bank of America Corp DEs holdings in bluebird bio were worth $5,855,000 as of its most []

Price T Rowe Associates Inc. MD trimmed its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 97.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 28,195 shares of the biotechnology companys stock after selling 923,645 shares during the quarter. Price T Rowe Associates []

Key Companies for Global CAR-T Cell Therapy Market Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc, Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation And More Key Companies for Global CAR-T Cell Therapy Market Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc, Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., Amgen, Celgene Corporation And More

bluebird bio, Inc. (NASDAQ:BLUE) reached a new 52-week low on Tuesday . The stock traded as low as $10.23 and last traded at $10.34, with a volume of 1155 shares. The stock had previously closed at $10.54. Several equities analysts recently weighed in on the company. William Blair assumed coverage on bluebird bio in a […]